Wall Street Zen lowered shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning.
A number of other research firms have also issued reports on BCAX. Wells Fargo & Company increased their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Morgan Stanley raised their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research note on Tuesday. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Citigroup initiated coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They set an “outperform” rating for the company. Finally, The Goldman Sachs Group raised their price objective on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $30.27.
View Our Latest Stock Analysis on Bicara Therapeutics
Bicara Therapeutics Stock Performance
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts predict that Bicara Therapeutics will post -3.37 EPS for the current year.
Insiders Place Their Bets
In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00. Following the completion of the sale, the chief operating officer owned 196,141 shares in the company, valued at $4,513,204.41. This trade represents a 5.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $22.88, for a total value of $125,840.00. Following the sale, the insider owned 55,286 shares of the company’s stock, valued at approximately $1,264,943.68. This trade represents a 9.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 174,310 shares of company stock worth $3,459,283 in the last quarter. Company insiders own 15.50% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Deutsche Bank AG lifted its holdings in Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after buying an additional 1,171 shares during the last quarter. Legal & General Group Plc lifted its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the last quarter. Mariner LLC lifted its holdings in Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after buying an additional 1,902 shares during the last quarter. Invesco Ltd. lifted its holdings in Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after buying an additional 1,962 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after buying an additional 2,447 shares during the last quarter.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Stories
- Five stocks we like better than Bicara Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
